Mixing medicines at Alliance

Hasenfuss, Marc
October 2002
Finance Week;10/25/2002, p28
Analyzes the business performance of South African drug firm Alliance Pharmaceuticals, a subsidiary of Forim Holdings. Continued decline of Alliance under the leadership of chief executive Meyer Gelbart; Possible growth of Alliance with a stronger involvement from shareholders Thebe Healthcare and Ian Black; Possible impact of a plan by Mutumwa Mawere to take a board seat at Forim.


Related Articles

  • A dose of good medicine. Hasenfuss, Marc // Finance Week;6/9/2003, p29 

    Looks at the prospects for South Africa-based Alliance Pharmaceutical Corp. for the second half of 2003. Emergence of a consortium led by Thebe and healthcare expert Ian Black; Shareholders' contention that management consistently underperformed its performance mandate; Trading margins; Cash...

  • Alliance submits new drug application.  // San Diego Business Journal;10/25/99, Vol. 20 Issue 43, p12 

    Focuses on the submission by San Diego, California-based Alliance Pharmaceutical Corp. of a drug application to the United States Food and Drug Administration for its ultrasound contrast agent called Imagent.

  • OTHER NEWS TO NOTE.  // BioWorld Today;11/26/2007, Vol. 18 Issue 228, p5 

    This section offers news briefs on pharmaceutical industry. Alliance Pharmaceutical Corp. decided to update its clinical development plan for Oxygent to focus primarily on supporting the initial clinical development of Oxygent in China. Inviragen LLC has received a $600,000 Small Business...

  • IN THE PIPELINE.  // Drug Utilization Review;Mar2001, Vol. 17 Issue 3, Special Section p8 

    Presents news briefs on the pharmaceutical industry as of March 2001. Suspension made by Alliance Pharmaceutical Corp. on enrollment in its Phase III study with its perflubron emulsion; Nonapproval letter from the United States Food and Drug Administration received by Aronex Pharmaceuticals for...

  • ALLIANCE PLANS EUROPEAN PHASE 3 STUDY FOR OXYGENT.  // Worldwide Biotech;May2002, Vol. 14 Issue 5, p3 

    Reports on the announcement of Alliance Pharmaceutical Corp. that representatives from Alliance and Baxter Healthcare Corp. have met with selected European regulatory authorities to review the clinical development plans for the intravascular oxygen carrier Oxygent.

  • Big lift for biomeds; FDA gives Alliance drug OK. Fikes, Bradley J. // San Diego Business Journal;8/23/93, Vol. 14 Issue 34, p5 

    Reports on the Food and Drug Administration's approval of a diagnostic drug produced by Alliance Pharmaceutical Corp. Imagent GI, a contrast agent for magnetic resonance imaging pictures of the bowel; Sales estimates; Market for temporary blood substitutes and cell oxygenator; Effect on San...

  • Alliance Pharmaceutical Corp.  // San Diego Business Journal;11/1/93, Vol. 14 Issue 44, Business action p1A 

    Introduces Alliance Pharmaceutical Corp.'s products based on perfluorochemicals. Temporary red blood cell substitute called Oxygent; `Liquid breathing' drug called LiquiVent; Oral contrast agent called Imagent GI; More.

  • OXYGENT REDUCES NEED FOR DONOR BLOOD IN PHASE 3 STUDY.  // Biotech Business;Oct2000, Vol. 13 Issue 10, p4 

    Reveals the results of a study citing that Oxygent from Alliance Pharmaceutical Corp. was found to significantly reduce the need for donor blood in patients undergoing surgical procedures.

  • Alliance Stock Dips Slightly After Rival Drug Approval. Webb, Marion // San Diego Business Journal;4/16/2001, Vol. 22 Issue 16, p6 

    Reports the stock decline of Alliance Pharmaceutical Corp. in San Diego, California. Percentage of stock of the rival drugmaker Biopure Inc.; Plan of the company to file for regulatory approval; Benefits of the partnership between Alliance and Baxter International Inc.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics